Literature DB >> 21696645

Delirium at the end of life.

Paul W Keeley1.   

Abstract

INTRODUCTION: Delirium is common in the last weeks of life, occurring in 26% to 44% of people with advanced cancer in hospital, and in up to 88% of people with terminal illness in the last days of life. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical question: What are the effects of interventions at the end of life in people with delirium caused by underlying terminal illness? We searched: Medline, Embase, The Cochrane Library, and other important databases up to February 2009 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS: We found three systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS: In this systematic review, we present information relating to the effectiveness and safety of the following interventions: artificial hydration; barbiturates; benzodiazepines; haloperidol; opioid switching; phenothiazines; and propofol.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 21696645      PMCID: PMC2907814     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  12 in total

Review 1.  Why are trials in palliative care so difficult?

Authors:  G E Grande; C J Todd
Journal:  Palliat Med       Date:  2000-01       Impact factor: 4.762

Review 2.  Methods for assessment of cognitive failure and delirium in palliative care patients: implications for practice and research.

Authors:  Marianne Hjermstad; Jon H Loge; Stein Kaasa
Journal:  Palliat Med       Date:  2004-09       Impact factor: 4.762

3.  Hypodermoclysis for control of dehydration in terminal-stage cancer.

Authors:  L Cerchietti; A Navigante; A Sauri; F Palazzo
Journal:  Int J Palliat Nurs       Date:  2000-09

4.  Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study.

Authors:  P G Lawlor; B Gagnon; I L Mancini; J L Pereira; J Hanson; M E Suarez-Almazor; E D Bruera
Journal:  Arch Intern Med       Date:  2000-03-27

5.  The use of phenobarbitone in the management of agitation and seizures at the end of life.

Authors:  L C Stirling; A Kurowska; A Tookman
Journal:  J Pain Symptom Manage       Date:  1999-05       Impact factor: 3.612

Review 6.  Survival prediction in terminal cancer patients: a systematic review of the medical literature.

Authors:  A Viganò; M Dorgan; J Buckingham; E Bruera; M E Suarez-Almazor
Journal:  Palliat Med       Date:  2000-09       Impact factor: 4.762

7.  Titrated intravenous barbiturates in the control of symptoms in patients with terminal cancer.

Authors:  W R Greene; W H Davis
Journal:  South Med J       Date:  1991-03       Impact factor: 0.954

8.  Delirium (acute confusional states).

Authors:  Z J Lipowski
Journal:  JAMA       Date:  1987-10-02       Impact factor: 56.272

Review 9.  Delirium in advanced cancer patients.

Authors:  Carlos Centeno; Alvaro Sanz; Eduardo Bruera
Journal:  Palliat Med       Date:  2004-04       Impact factor: 4.762

10.  Cognitive failure in patients with terminal cancer: a prospective study.

Authors:  E Bruera; L Miller; J McCallion; K Macmillan; L Krefting; J Hanson
Journal:  J Pain Symptom Manage       Date:  1992-05       Impact factor: 3.612

View more
  1 in total

1.  Neurolytic celiac plexus block reduces occurrence and duration of terminal delirium in patients with pancreatic cancer.

Authors:  Young-Chang P Arai; Makoto Nishihara; Kunio Kobayashi; Tamotsu Kanazawa; Nobuhiko Hayashi; Yukio Tohyama; Kikuyo Nishida; Maki Arakawa; Chiharu Suzuki; Akiko Kinoshita; Miki Kondo; Satuki Matsubara; Nami Yokoe; Ruiko Hayashi; Aya Ohta; Jun Sato; Takahiro Ushida
Journal:  J Anesth       Date:  2012-09-19       Impact factor: 2.078

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.